

# CONTENTS

<b>Chapter 1 : General Introduction</b>	<b>1-33</b>
1.1: Amphiphilic block copolymers (ABCs)	2
1.2: Self-assembly of amphiphilic block copolymers (ABCs)	5
1.3: Pluronic® polymers: Versatile amphiphilic block copolymers	8
1.4: Chemistry of Pluronics	9
1.5: Self-assemblies of Pluronic polymers	10
1.6: Pluronic micelles in drug delivery	15
1.7: References	20
<b>Chapter 2 : Materials, Experimental Design, and Characterization Methods</b>	<b>34-61</b>
<b>2.1: Materials</b>	<b>35</b>
2.1.1: Pluronic® polymers	35
2.1.2: Biocompatible materials	36
2.1.2.1: <i>L-<math>\alpha</math>-Phosphatidylcholine</i>	36
2.1.2.2: <i>D-<math>\alpha</math>-Tocopherol polyethylene glycol 1000 succinate</i>	37
2.1.2.3: <i>Stearic Acid</i>	38
2.1.3: Lipophilic drugs	39
2.1.3.1: <i>Quercetin</i>	39
2.1.3.2: <i>Curcumin</i>	41
2.1.3.3: <i>Glipizide</i>	43
2.1.4: Other materials used in biological investigations	45
<b>2.2: Experimental design</b>	<b>46</b>
2.2.1: D-Optimal Design	46
2.2.2: Central Composite Design	47
<b>2.3: Characterization methods</b>	<b>49</b>
2.3.1: Determination of critical micelle concentration	49
2.1.3.2: <i>CMC using UV-Vis Spectroscopy</i>	49
2.1.3.2: <i>CMC using Fluorescence Spectroscopy</i>	50

2.3.2: CPT measurements	51
2.3.3: Drug solubility determinations	51
2.3.4: Structural characterization methods	52
2.3.4.1: <i>DLS analysis</i>	52
2.3.4.2: <i>SEM measurements</i>	52
2.3.4.3: <i>TEM analysis</i>	53
2.3.4.4: <i>SANS analysis</i>	53
2.3.4.5: <i>Rheology/Viscosity measurements</i>	56
2.3.5: Solid state characterization methods	57
2.3.5.1: <i>FTIR measurements</i>	57
2.3.5.2: <i>XRD analysis</i>	57
2.3.5.3: <i>DSC analysis</i>	57
2.3.5.4: <i>NMR spectroscopy</i>	58
2.3.5.5: <i>Stability study</i>	58
2.3.6: Biological investigations	58
<b>2.4: References</b>	59
<b>Chapter 3 : Mixed Pluronic Self-assemblies for Quercetin Drug for Anticancer Evaluations</b>	<b>62-86</b>
<b>3.1: Introduction</b>	63
<b>3.2: Experimental Section</b>	66
3.2.1: Preparation of the mixed P123/F88 micelles	66
3.2.2: Characterization methods	66
3.2.3: <i>In-vitro</i> release study of QCN-incorporated mixed P123/F88 micelles	66
3.2.4: <i>In-vitro</i> antioxidant activity of QCN-incorporated mixed P123/F88 micelles	67
3.2.5: <i>In-vitro</i> cell proliferation activity studies	67
<b>3.3: Results and discussion</b>	69
3.3.1: Self-aggregation of mixed P123/F88 micelles	69
3.3.2: CPT of mixed P123/F88 micelles	70
3.3.3: Size and zeta potential of QCN drug-free mixed P123/F88 micelles	70
3.3.4: Solubilization of QCN drug in the mixed P123/F88 micelles	72

3.3.5: Characterization of QCN-incorporated mixed P123/F88 micelles	73
3.3.6: Compatibility of QCN drug with mixed P123/F88 micelles	75
3.3.7: Storage stability study of QCN-incorporated mixed P123/F88 micelles	77
3.3.8: <i>In-vitro</i> drug release profile	78
3.3.9: <i>In-vitro</i> antioxidant activity	79
3.3.10: <i>In-vitro</i> cell proliferation activity	80
<b>3.4: References</b>	82
<b>Chapter 4 : Mixed Pluronic/phosphatidylcholine self-assemblies for curcumin drug for antimicrobial evaluations</b>	<b>87-116</b>
<b>4.1: Introduction</b>	88
<b>4.2: Experimental Section</b>	90
4.2.1: Optimization and fabrication of PFPC and CUR-PFPC mixed polymeric micellar formulations	91
4.2.1.1: <i>Statistical optimization through D-optimal design</i>	91
4.2.1.2: <i>Fabrication of PFPC and CUR-PFPC mixed polymeric nanomicellar formulations</i>	92
4.2.1.3: <i>Formulation optimization</i>	93
4.2.2: Characterization method	93
4.2.3: <i>In-vitro</i> biological investigations	93
4.2.3.1: <i>In-vitro % drug release</i>	93
4.2.3.2: <i>In-vitro Antioxidant Assay</i>	94
4.2.3.3: <i>In-vitro antimicrobial activity</i>	94
4.2.3.4: <i>Statistical analysis</i>	95
<b>4.3: Results and discussion</b>	96
4.3.1: Statistical analysis of the D-optimal design	96
4.3.1.1: <i>Solubility model analysis</i>	97
4.3.1.2: <i>% DL model analysis</i>	98
4.3.1.3: <i>% EE model analysis</i>	98
4.3.2: Characterization of PFPC and CUR-PFPC mixed nanomicellar formulations	103
4.3.2.1: <i>Mixed micellar size, zeta potential, and morphological</i>	103

<i>investigations</i>	
4.3.2.2: <i>CUR compatibility and stability in mixed micellar formulation investigation</i>	105
4.3.3: <i>In-vitro</i> biological investigations	107
4.3.3.1: <i>In-vitro</i> release study	107
4.3.3.2: <i>In-vitro</i> antioxidant activity	108
4.3.3.3: <i>In-vitro</i> antimicrobial activity	108
<b>4.4: References</b>	112
<b>Chapter 5 : Mixed Pluronics/phosphatidylcholine self-assemblies for curcumin drug for anticancer evaluations</b>	<b>117-145</b>
<b>5.1: Introduction</b>	118
<b>5.2: Experimental Section</b>	121
5.2.1: Preparation of mixed PC/Pluronic micellar systems	121
5.2.2: Preparation of CUR-loaded mixed PC/Pluronic micellar systems	121
5.2.3: Characterization method	122
5.2.4: <i>In-vitro</i> curcumin release study	123
5.2.5: <i>In-vitro</i> antioxidant activity	123
5.2.6: <i>In-vitro</i> cell proliferation assay	124
5.2.7: <i>In-vitro</i> cell viability assay	124
<b>5.3: Results and Discussion</b>	125
5.3.1: Aggregation behavior of mixed PC/Pluronic micellar solutions	125
5.3.2: Solubility of CUR in mixed PC/Pluronic micellar solutions	133
5.3.3: Location of CUR in the mixed PC/Pluronic micellar system	134
5.3.4: Biological evaluation	135
5.3.4.1: <i>In-vitro</i> release study	135
5.3.4.2: <i>Antioxidant activity analysis</i>	136
5.3.4.3: <i>Cell proliferation activities</i>	137
5.3.4.4: <i>Cell viability assays</i>	138
<b>5.4: References</b>	140

**Chapter 6 : Mixed Pluronic/Vitamin E conjugates self-  
assemblies for glipizide drug for antidiabetic  
evaluations**

**146-176**

<b>6.1: Introduction</b>	147
<b>6.2: Experimental Section</b>	150
6.2.1: Methods	150
6.2.1.1: <i>Synthesis of SA-F127</i>	150
6.2.1.2: <i>Experimental Design</i>	150
6.2.1.3: <i>Fabrication of GLN-PMM</i>	151
6.2.1.4: <i>Formulation optimization</i>	152
6.2.2: Characterization methods	152
6.2.3: Biological Investigations	152
6.2.3.1: <i>In-vitro drug release and kinetic study</i>	152
6.2.3.2: <i>Ex-vivo permeation study</i>	153
6.2.3.3: <i>In-vivo anti-diabetic study</i>	153
<b>6.3: Results and Discussion</b>	155
6.3.1: Characterization of SA-F127	155
6.3.2: Solubility studies	156
6.3.3: Optimization through CCD	157
6.3.3.1: <i>The effect of studied variable on particle size of GLN-PMM system</i>	158
6.3.3.2: <i>The effect of studied variable on PDI of GLN-PMM system</i>	158
6.3.3.3: <i>The effect of studied variable on %DL of GLN-PMM system</i>	159
6.3.3.4: <i>The effect of studied variable on %EE of GLN-PMM system</i>	159
6.3.4: Characterization of optimized PMM and GLN-PMM system	161
6.3.4.1: <i>CMC</i>	161
6.3.4.2: <i>Particle size and morphological characterization</i>	161
6.3.4.3: <i>Solid state characterization</i>	164
6.3.5: Location of GLN solubilization in GLN-PMM system	165
6.3.6: Stability Study	167

6.3.7: Biological Investigation	168
6.3.7.1: <i>In-vitro</i> Drug release profile	168
6.3.7.2: <i>Ex-vivo</i> permeation study	169
6.3.7.3: <i>In-vivo</i> anti-diabetic study	170
6.4: References	171
<b>Chapter 7 : Summary and Conclusions</b>	<b>177-185</b>
<b><i>List of Publications</i></b>	<b>186-188</b>
<b><i>List of Presentations</i></b>	<b>189-191</b>
<b><i>Awards/Achievements</i></b>	<b>192-193</b>